Immuneering Corp financial data

Symbol
IMRX on Nasdaq
Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1129% % 6.8%
Debt-to-equity 13% % -11%
Return On Equity -73% % 7.2%
Return On Assets -65% % 5.9%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float $38,000,000 USD -84%
Weighted Average Number of Shares Outstanding, Basic 39,670,095 shares 33%
Weighted Average Number of Shares Outstanding, Diluted 39,670,095 shares 33%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $47,651,002 USD 5.8%
General and Administrative Expense $16,501,138 USD -1.6%
Operating Income (Loss) $64,181,407 USD -3.8%
Net Income (Loss) Attributable to Parent $62,496,374 USD -7.6%
Earnings Per Share, Basic -1 USD/shares 8.7%
Earnings Per Share, Diluted -1 USD/shares 8.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $227,563,077 USD 403%
Assets, Current $229,101,829 USD 315%
Property, Plant and Equipment, Net $892,553 USD -26%
Operating Lease, Right-of-Use Asset $3,411,693 USD -9%
Goodwill $6,690,431 USD 0%
Other Assets, Noncurrent $631,297 USD -51%
Assets $241,056,266 USD 252%
Accounts Payable, Current $1,600,274 USD -18%
Accrued Liabilities, Current $7,483,142 USD 63%
Liabilities, Current $9,545,265 USD 38%
Operating Lease, Liability, Noncurrent $3,534,569 USD -9.7%
Liabilities $13,079,834 USD 21%
Accumulated Other Comprehensive Income (Loss), Net of Tax $0 USD
Retained Earnings (Accumulated Deficit) $268,740,074 USD -30%
Stockholders' Equity Attributable to Parent $227,976,432 USD 295%
Liabilities and Equity $241,056,266 USD 252%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $14,080,638 USD 9.1%
Net Cash Provided by (Used in) Financing Activities $13,810,559 USD 1309%
Net Cash Provided by (Used in) Investing Activities $21,392,522 USD 13%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $279,024 USD -104%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $227,563,077 USD 403%
Deferred Tax Assets, Valuation Allowance $58,994,707 USD 36%
Deferred Tax Assets, Gross $59,339,161 USD 36%
Operating Lease, Liability $3,916,329 USD -7.7%
Depreciation $90,209 USD 18%
Payments to Acquire Property, Plant, and Equipment $8,945 USD -76%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $62,504,219 USD -7.6%
Lessee, Operating Lease, Liability, to be Paid $5,418,174 USD -12%
Property, Plant and Equipment, Gross $2,222,896 USD 0.94%
Operating Lease, Liability, Current $381,760 USD 18%
Lessee, Operating Lease, Liability, to be Paid, Year Two $784,737 USD 3%
Lessee, Operating Lease, Liability, to be Paid, Year One $761,877 USD 3%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,501,845 USD -21%
Lessee, Operating Lease, Liability, to be Paid, Year Three $808,278 USD 3%
Deferred Tax Assets, Operating Loss Carryforwards $25,300,681 USD 32%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $1,136,528 USD 62%
Lessee, Operating Lease, Liability, to be Paid, Year Four $832,527 USD 3%
Operating Lease, Payments $183,546 USD -4.7%
Additional Paid in Capital $496,653,023 USD 88%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets $29,267 USD 0%
Depreciation, Depletion and Amortization $334,745 USD -6.9%
Deferred Tax Assets, Net of Valuation Allowance $344,454 USD -12%
Share-based Payment Arrangement, Expense $6,398,033 USD -0.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%